Table 4.
ORs for analysis of correlation between exposure and genotypes
| Genotypes |
Cumulative VCM exposure |
|||||
|
≤ 15 000 mg |
> 15 000 mg |
|||||
| Control | Liver lesion | OR (95% CI) | Control | Liver lesion | OR (95% CI) | |
| GSTT1 | ||||||
| Null | 15 | 23 | 1 | 16 | 14 | 1 |
| GSTM1 | 17 | 9 | 0.3 (0.1-0.9)a | 10 | 12 | 1.4 (0.5-4.1) |
| GSTM1 | ||||||
| Non-null | 21 | 21 | 1 | 16 | 15 | 1 |
| Null | 11 | 11 | 1.0 (0.4-2.8) | 10 | 11 | 1.2 (0.4-3.6) |
| CYP2E1 | ||||||
| c1c1 | 23 | 16 | 1 | 20 | 11 | 1 |
| c1c2/ c2c2 | 9 | 16 | 2.6 (0.9-7.2) | 6 | 15 | 4.6 (1.4-15.1)a |
| ALDH2 | ||||||
| 1-1 | 20 | 22 | 1 | 17 | 14 | 1 |
| 1-2/2-2 | 12 | 10 | 0.8 (0.3-2.1) | 9 | 12 | 1.6 (0.5-5.0) |
| ADH2 | ||||||
| 1-1 | 2 | 8 | 1 | 2 | 1 | 1 |
| 1-2/2-2 | 30 | 24 | 0.2 (0.1-1.0)a | 24 | 23 | 2.1 (0.2-24.5) |
a
P < 0.05 vs ≤ 15 000 mg group.